ION Breast Cancer Clinical Pathways - ION Solutions

Taxotere (Docetaxel) Paraplatin (Carboplatin) Herceptin (Trastuzumab) EP=Moderate;FN˃20%Docetaxel 75mg/m 2 D1Carboplatin AUC 6 D1Trastuzumab 4mg/kg D1 (Cycle 1 only)2mg/kgD1, D8, D15q 21 Day Cycle x 6 CyclesThen continue:Trastuzumab 6mg/kg D1q 21 Day Cycle to complete 1 year of therapy>> J Clin Oncol 25:18S (June 20 suppl) Abstract 19647, 2007Adriamycin (Doxorubicin) Cytoxan (Cyclophosphamide) Followed by Taxotere(Docetaxel) Herceptin (Trastuzumab) EP=High; FN=10%-20%Doxorubicin 60mg/m2 D1Cyclophosphamide 600mg/m2 D1q 14 or q 21 Day Cycle x 4 CyclesFollowed by:Docetaxel 100 mg/m 2 D1Trastuzumab 4mg/kg D1 (Cycle 1 only)2mg/kgD1, D8, D15q 21 Day Cycle x 4 CyclesThen continue:Trastuzumab 6mg/kg D1q 21 Day Cycle x 13 Cycles>> NEnglJMed2005Oct;353(16):1673-84Taxotere (Docetaxel) Cytoxan (Cyclophosphamide) Herceptin (Trastuzumab)EP=Moderate; FN˃20%Docetaxel 75mg/m2 D1Cyclophosphamide 600mg/m2 D1Trastuzumab 8mg/kg D1 (Cycle 1 only)6mg/kgD1 (or weekly equivalent)q 21 Day Cycle x 4 or 6 CyclesThen continue:Trastuzumab 6mg/kg D1q 21 Day Cycle to complete 1 year of therapy>> JClinOncol2006Dec1;24(34):5381-7Clinical Trial:Screen patient for clinical trial. Check www.clinicaltrials.gov for available trials.Best Supportive Care and/or Hospice:Consider supportive care options and Hospice when appropriate.Page 8 of 39© 2013 by ION Solutions. All rights reserved